Identification of a Mutated Receptor-Like Protein Tyrosine Phosphatase κ as a Novel, Class II HLA-Restricted Melanoma Antigen1
暂无分享,去创建一个
P. Robbins | G. Parmiani | C. Castelli | L. Rivoltini | A. Greco | A. Mazzocchi | F. Rini | Paola Deho | P. Squarcina | L. Novellino | N. Renkvist
[1] G. Linette,et al. Antimelanoma Activity of CTL Generated from Peripheral Blood Mononuclear Cells After Stimulation with Autologous Dendritic Cells Pulsed with Melanoma gp100 Peptide G209-2M Is Correlated to TCR Avidity , 2002, The Journal of Immunology.
[2] Francesco M Marincola,et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? , 2002, Journal of the National Cancer Institute.
[3] F. Marincola,et al. Identification of a Mutated Fibronectin As a Tumor Antigen Recognized by CD4+T Cells , 2002, The Journal of experimental medicine.
[4] J. Trent,et al. Characterization of a complex chromosome rearrangement involving 6q in a melanoma cell line by chromosome microdissection. , 2002, Cancer genetics and cytogenetics.
[5] A. Maitra,et al. Loss of heterozygosity analysis of cutaneous melanoma and benign melanocytic nevi: laser capture microdissection demonstrates clonal genetic changes in acquired nevocellular nevi. , 2002, Human pathology.
[6] P. Roche,et al. Trafficking of MHC class II molecules in the late secretory pathway. , 2002, Current opinion in immunology.
[7] H. Ploegh,et al. A closer look at proteolysis and MHC-class-II-restricted antigen presentation. , 2002, Current opinion in immunology.
[8] Zhon-Yin Zhang,et al. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. , 2002, Annual review of pharmacology and toxicology.
[9] M. Herlyn,et al. Protein tyrosine phosphatase genes downregulated in melanoma. , 2001, The Journal of investigative dermatology.
[10] Rong Wang,et al. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. , 2001, Trends in immunology.
[11] E. Schaftingen,et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. , 2001, Cancer research.
[12] P. Robbins,et al. A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.
[13] R. Offringa,et al. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide. , 2000, Cancer research.
[14] S. H. van der Burg,et al. Importance of CD4(+) T helper cell responses in tumor immunity. , 2000, Immunology letters.
[15] P. Coulie,et al. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. , 2000, Cancer research.
[16] J. Sap,et al. Emerging issues in receptor protein tyrosine phosphatase function: lifting fog or simply shifting? , 2000, Journal of cell science.
[17] M. Vikkula,et al. High Frequency of Autologous Anti-Melanoma CTL Directed Against an Antigen Generated by a Point Mutation in a New Helicase Gene1 , 2000, The Journal of Immunology.
[18] G. Plautz,et al. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. , 2000, Critical reviews in immunology.
[19] F. Marincola,et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.
[20] A. Houghton,et al. A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. , 1999, Journal of immunology.
[21] S. Rosenberg,et al. Identification of a Novel Major Histocompatibility Complex Class II–restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.
[22] B. Moss,et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[23] J. Shabanowitz,et al. Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.
[24] C. Lowenstein,et al. The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.
[25] Spyros A. Kalams,et al. The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses , 1998, The Journal of experimental medicine.
[26] R. Offringa,et al. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. , 1998, Seminars in immunology.
[27] R. Siebert,et al. Cytogenetical assignment and physical mapping of the human R-PTP-kappa gene (PTPRK) to the putative tumor suppressor gene region 6q22.2-q22.3. , 1998, Genomics.
[28] M. Maio,et al. Immunogenicity of the ALLAVGATK (gp10017 – 25) peptide in HLA‐A3.1 melanoma patients , 1998, European journal of immunology.
[29] C. Melief,et al. Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.
[30] B. Neel,et al. Protein tyrosine phosphatases in signal transduction. , 1997, Current opinion in cell biology.
[31] M. Houghton,et al. Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles , 1997, Journal of virology.
[32] H. Ha,et al. Molecular cloning and chromosomal localization of a human gene homologous to the murine R-PTP-κ, a receptor-type protein tyrosine phosphatase , 1997 .
[33] A. Anichini,et al. Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. , 1996, Journal of immunology.
[34] A. Ullrich,et al. Association of Human Protein-tyrosine Phosphatase κ with Members of the Armadillo Family* , 1996, The Journal of Biological Chemistry.
[35] A Sette,et al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.
[36] E. Appella,et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.
[37] M. Serrano,et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.
[38] J. Sap,et al. Homophilic Interactions Mediated by Receptor Tyrosine Phosphatases μ and κ. A CRITICAL ROLE FOR THE NOVEL EXTRACELLULAR MAM DOMAIN (*) , 1995, The Journal of Biological Chemistry.
[39] T. Hunter,et al. Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling , 1995, Cell.
[40] J. Schlessinger,et al. Receptor tyrosine phosphatase R-PTP-kappa mediates homophilic binding , 1994, Molecular and cellular biology.
[41] A. Anichini,et al. Use of the Vδ1 Variable Region in the Functional T‐Cell Receptor α Chain of a WT31+ Cytotoxic T Lymphocyte Clone which Specifically Recognizes HLA‐A2 Molecule , 1992 .
[42] J. Rothbard,et al. Peptides recognized by class I restricted T cells also bind to MHC class II molecules. , 1990, International immunology.